Maintaining a steady state of mucus
barrier is an important potential
target for polyphenol to exert its anticolitis activity. This study
elucidates the pivotal role of polyphenol rosmaric acid (RA) in regulating
the mucus barrier function and alleviating inflammation by identifying
its gut microbiota-derived metabolites and evaluating its inhibitory
effect on inflammasomes in colitis mice. Results demonstrated that
RA treatment promoted the proliferation of goblet cells and restored
the level of mucus secretion, especially Muc2. RA reshaped the microbiota
of colitis mice, particularly the boost of core probiotics, such as
p. Bacteroidaceae, f. Muribaculaceae, g. Muribaculaceae, g. Alistipes, and g. Clostridia_UCG-014. Nontargeted metabonomics
and targeted metabonomics confirmed a significant increase in the
bile acids and their metabolites (7-sulfocholic acid, stercobilin,
chenodeoxycholic acid 3-sulfate, chenodeoxycholic acid sulfate, and
ursodeoxycholic acid 3-sulfate), indole metabolites ((R)-2,3-dihydro-3,5-dihydroxy-2-oxo-3-indoleacetic
acid, frovatriptan, 3-formyl-6-hydroxyindole, and brassicanal A),
and short-chain fatty acids (SCFAs) (acetic acid, butyric acid, isobutyric
acid, isovaleric acid, and valeric acid) that contributed to the strengthened
mucus barrier function. In addition, being absorbed mainly in the
lower digestive tract, RA inhibited the overexpression of inflammasomes
(especially NLRP6) that occurred in colitis mice to promote the mucus
secretion of goblet cells. These data confirmed that RA, as a promising
candidate to enhance gut health, restored colonic mucus secretion
in colitis mice by mediating the production of gut microbiota-derived
metabolites and the overexpression of inflammasomes. The presented
study provides scientific evidence explaining the apparent paradox
of low bioavailability and high bioactivity in polyphenols.